- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01868412
Resin Salve Versus Honey Treatment in Wound Care
January 15, 2016 updated by: Kuopio University Hospital
Comparison of Resin Salve and Medical Honey in Wound Care in Vascular Surgery Patients - A Prospective, Randomized and Controlled Clinical Trial
In recent years, salve prepared from Norway spruce (Picea abies) resin and refined honey from manuka myrtle (Leptospermum scoparium), has successfully been used in medical context to treat both acute and chronic surgical wounds.
The objective of this prospective, randomized and controlled clinical trial is to investigate healing rate and healing time of surgical wounds in patients, who have undergone peripheral vascular surgery, and whose complicated wounds are candidate for topical treatment with the resin or honey.
In addition, factors contributing with delayed wound healing, antimicrobial properties, safety and cost-effectiveness of the resin salve and medical honey will be analyzed.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kuopio, Finland, 70200
- Kuopio University Hospital
-
Kuopio, Finland, FI-70029
- Kuopio University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 96 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Infected of non-infected acute or chronic wound after vascular surgery.
- Need for topical wound care.
- Need for wound healing follow-up at the surgical outpatient department.
Exclusion Criteria:
- Life expectancy less than 6 months.
- Advanced malignant disease.
- Need for extensive surgical wound revision or skin transplantation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Resin & honey
Abilar 10% resin salve
|
The resin salve may be spread directly onto the wound, after which the area is covered with a bandage suitable for local wound care.
The bandage prohibits salve from moving away from the wound area.
If the skin condition is more widespread or contains cavities or fistulae, the salve may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel.
Bandages are changed every 1-3 days, depending on the degree of infection and amount of wound secretion.
|
|
Active Comparator: Resin vs. honey
Activon Tube 25 g
|
Wound care with the medical honey is carried out in the same manner than the resin salve treatment: honey may be spread directly onto the wound and the wound area is covered with a bandage suitable for local wound care.
Similarly, if the skin condition is more widespread or wound contains cavities or fistulae, the medical honey may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel.
Bandages are changed every 1-3 days, depending on the severity of infection and amount of wound secretion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Wound Healing
Time Frame: 6 months
|
Healing rate of acute or chronic surgical wound within 6 months after vascular surgery (%).
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Contributors for Wound Healing
Time Frame: 6 months
|
Contributors in terms of risk ratio (RR) to delayed wound healing.
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Other Pre-specified Outcome Measure
Time Frame: 6 months
|
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Tommi Auvinen, MD, Kuopio University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2013
Primary Completion (Actual)
January 1, 2016
Study Completion (Actual)
January 1, 2016
Study Registration Dates
First Submitted
May 8, 2013
First Submitted That Met QC Criteria
June 3, 2013
First Posted (Estimate)
June 4, 2013
Study Record Updates
Last Update Posted (Estimate)
January 18, 2016
Last Update Submitted That Met QC Criteria
January 15, 2016
Last Verified
January 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KUH15101075
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Wound Infection
-
Pulmatrix Inc.TerminatedPost Operative Wound Infection | Postoperative Wound Infection-deepUnited States
-
Brigham and Women's HospitalRecruitingWound Infection and Wound HealingUnited States
-
Carilion ClinicSmith & Nephew, Inc.; DeRoyal Industries, Inc.CompletedImpaired Wound Healing | Postoperative Wound Infection-deepUnited States
-
PolyPid Ltd.CompletedPostoperative Wound Infection Superficial Incisional | Postoperative Wound Infection Deep Incisional Surgical SiteIsrael
-
Children's Healthcare of AtlantaWithdrawnPostoperative Wound InfectionUnited States
-
Military Medical AcademyRecruitingPostoperative Wound Infection Superficial Incisional | Postoperative Wound Infection Deep Incisional Surgical SiteBulgaria
-
Prof. Dr. Bülent M. ErtuğrulBaşakşehir Çam & Sakura City HospitalActive, not recruitingIdentification | Wound Infection BacterialTurkey (Türkiye)
-
PfizerCompletedSurgical Wound Infection | Postoperative Wound Infection
-
HITEC-Institute of Medical SciencesCompletedWound Infection | Wound Dehiscence | Wound Surgical | Wound BleedingPakistan
-
Universitat Internacional de CatalunyaHospital de GranollersCompletedSurgical Wound Infection | Postoperative Wound Infection | Postoperative Wound Infection Superficial Incisional | Preventive TherapySpain
Clinical Trials on Abilar 10% resin salve
-
Repolar Pharmaceuticals OyPrinceton Consumer ResearchCompletedSkin Sensitization | Skin IrritationUnited Kingdom
-
Janne J. JokinenRepolar Ltd.CompletedDiabetes Mellitus | Diabetes Complications | Diabetic Neuropathies | Wound InfectionPoland
-
Repolar Pharmaceuticals OyBusiness Finland; Complife Italia SrlCompletedAtopy | Skin Barrier to Water LossItaly
-
Kafrelsheikh UniversityCompletedEndodontically Treated Teeth | Anterior TeethEgypt
-
Yokohama City UniversityEA Pharma Co., Ltd.CompletedNonalcoholic Steatohepatitis | Nonalcoholic Fatty LiverJapan
-
Yonsei UniversityCompletedHyperlipidemiaKorea, Republic of
-
SanofiActive, not recruitingMultiple SclerosisCanada, Mexico, Spain, Germany, Greece, Israel, China, Portugal, Saudi Arabia, Argentina, Turkey (Türkiye), South Korea, United States, Belgium, Brazil, Bulgaria, Chile, Czechia, Hungary, India, Italy, Japan, Poland, Ukraine, United Kingdom and more
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedClassic Hodgkin Lymphoma | Lugano Classification Stage III Hodgkin Lymphoma AJCC v8 | Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8United States